Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Yogurt vs. jelly: which boosts overnight muscle recovery?

NCT ID NCT06986356

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating a high-protein yogurt after exercise helps muscles recover better overnight compared to a flavored water jelly. 26 healthy adults aged 18-45 completed exercise sessions and had their muscle function, soreness, and readiness to exercise measured 12 and 24 hours later. The goal was to see if the yogurt could speed up recovery and improve next-day performance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Feb 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 and ≤ 45 years * Body Mass Index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 * Written informed consent * Willingness and ability to comply with the protocol in the opinion of the Investigator * Judged by the Investigator to be in good health as assessed by a health screening questionnaire * Currently identifies as the same biological sex as at birth Exclusion Criteria: * Any known ongoing medical condition that interferes significantly with absorption and digestion and/or gastrointestinal (GI) function (e.g. inflammatory bowel disease, gastroesophageal reflux disease, celiac disease, diaphragmatic hernia or diaphragmatic surgery, gastric ulcer, gastritis, gall bladder problems, pancreatitis, GI cancer, oesophageal and/or gastric surgery), in opinion of the investigator. * Known musculoskeletal or soft tissue injury * Known cardiovascular disease, disease related to the immune system and/or the respiratory system * Known renal or hepatic failure or known thyroid dysfunction * Known Diabetes Mellitus type I or type II, insulin resistance or metabolic syndrome * Any ongoing cancer (except for basal cell carcinoma) and/ or cancer treatment * Known anaemia or low haemoglobin or low iron status * Any known bleeding disorder or reaction to withdrawal of blood samples * Use of oral and systemic use of prokinetics, laxatives, antidiarrheals, anticoagulants within 2 weeks prior to screening * Use of systemic antibiotics within 4 weeks prior to screening * Any known allergies or intolerances to ingredients of the study product, i.e. cow's milk allergies, lactose intolerance * Adherence to a strict dietary regime (e.g. vegetarian/ vegan/ paleo/ketogenic/intermittent fasting/ high protein diet (\>1.6 g/kg body weight/day) or a weight loss program) * Use of any nutritional supplements or additional protein supplements or nutritional support within 4 weeks prior to screening * Falling below or exceeding the classification of Tier 1 or Tier 2 (McKay et al 2022, IJSPP. 17, 317-331). Ranging from minimum of meeting WHO guidelines for physical activity up to training \~3 times per week and local level representation in a sport. * Known pregnancy and/or lactation * Current smoking or stopped smoking for \<1 month prior to screening (except for incidental smoking of ≤3 cigarettes/cigars/pipes per week on average in the last month) * Average alcohol use of \>21 glasses\* per week for men or \>14 glasses per week for women (on average during the last 6 months) or drug/ medicine abuse in opinion of the investigator * Participation in any other clinical study with investigational or marketed products concomitantly or within 4 weeks before screening. * Major medical or surgical event requiring hospitalization within the preceding 3 months and/or scheduled in the period of study participation relevant in the opinion of the Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Myalgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northumbria University

    Newcastle upon Tyne, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.